SCHEMBL21186346

SCHEMBL21186346

CC(=O)N[C@H](C(C)=O)C1CC1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PREP P48147 1/20 0.32
FAP Q12884 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31
ALOX15 P16050 1/20 0.31
NFKB1 P19838 1/20 0.31
PTGS2 P35354 1/20 0.31
THPO P40225 1/20 0.31
RECQL P46063 1/20 0.31
BLM P54132 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
EPHX2 P34913 1/20 0.31
ALOX5 P09917 1/20 0.30
ALDH1A1 P00352 1/20 0.30
DPP4 P27487 1/20 0.30
DPP8 Q6V1X1 1/20 0.30
DPP9 Q86TI2 1/20 0.30
MMP13 P45452 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12965975 1.00 PREP (0.32) PREPFAPKDM4EMAPTTHRB
SCHEMBL20707095 0.91 MMP2 (0.39) PREPFAPKDM4EMAPTSMN1; SMN2
SCHEMBL21186419 0.91 MMP2 (0.39) PREPFAPKDM4EMAPTSMN1; SMN2
SCHEMBL19083735 0.84 SMN1; SMN2 (0.39) PREPFAPKDM4EMAPTTHRB
SCHEMBL31730569 0.84 SMN1; SMN2 (0.39) PREPFAPKDM4EMAPTTHRB
SCHEMBL13544389 0.84 SMN1; SMN2 (0.39) PREPFAPKDM4EMAPTTHRB
SCHEMBL890115 0.80 AAK1 (0.32) MAPTSMN1; SMN2ALDH1A1
SCHEMBL12402478 0.80 AAK1 (0.32) MAPTSMN1; SMN2ALDH1A1
SCHEMBL890063 0.80 AAK1 (0.32) MAPTSMN1; SMN2ALDH1A1
SCHEMBL19486072 0.80 DPP4 (0.34) PREPFAPSMN1; SMN2EPHX2ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338588-A1 Granzyme B Directed Imaging and Therapy THE GENERAL HOSPITAL CORPORATION 2023-10-26 US disclosed
US-20230338588-A1 Granzyme B Directed Imaging and Therapy THE GENERAL HOSPITAL CORPORATION 2023-10-26 US disclosed
US-11559590-B2 Granzyme B directed imaging and therapy THE GENERAL HOSPITAL CORPORATION (US) 2023-01-24 US disclosed
US-20190224348-A1 Granzyme B Directed Imaging and Therapy THE GENERAL HOSPITAL CORPORATION 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11559590-B2 Granzyme B directed imaging and therapy GZMB, CTSB, PRF1 PREP 494/4885FAP 421/4885KDM4E 4633/4885
US-20230338588-A1 Granzyme B Directed Imaging and Therapy GZMB, CTSB, PRF1 PREP 494/4885FAP 421/4885KDM4E 4633/4885
US-20190224348-A1 Granzyme B Directed Imaging and Therapy GZMB, CTSB, PRF1 PREP 494/4885FAP 421/4885KDM4E 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.